Results 151 to 160 of about 9,247 (168)

Daratumumab

Reactions Weekly, 2017
openaire   +2 more sources

Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma

Clinical Infectious Diseases, 2021
Heechul Nam, Jong Young Choi, Chang-Ki Min   +2 more
exaly  

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

Cancers, 2021
Meletios Dimopoulos, Sonja Zweegman, Tuna Mutis   +2 more
exaly  

Daratumumab: A review of current indications and future directions

Seminars in Oncology, 2022
Dickran Kazandjian, Candis Morrison
exaly  

Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations

Annals of Pharmacotherapy, 2022
, , Justin Arnall
exaly  

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Cells, 2020
Roberto Ria, Clélia Tiziana Storlazzi, Antonio Giovanni Solimando   +2 more
exaly  

Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab

Clinical Lymphoma, Myeloma and Leukemia, 2020
Peter Voorhees, , Allison Martin
exaly  

Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel

Critical Reviews in Oncology/Hematology, 2022
Corrado Girmenia, Antonio Rosato, Francesco Di Raimondo   +2 more
exaly  

Daratumumab for the treatment of multiple myeloma

Expert Opinion on Biological Therapy, 2017
Cyrille Touzeau, Philippe Moreau
exaly  

Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol

Clinical Lymphoma, Myeloma and Leukemia, 2020
Peter Voorhees, Issam Hamadeh, Ekaterina Kachur   +2 more
exaly